Mebendazole Overview
What mebendazole is, why it is studied in oncology, and where the evidence is strongest
Mebendazole is best known as an over-the-counter anti-parasitic medicine, but it is now attracting serious interest as a multi-target repurposed cancer therapy. In oncology research, it is relevant because it interferes with cell division, blocks angiogenesis, disrupts cancer survival signalling, and may enhance anti-tumour immune activity.
At a Glance
What it is: A benzimidazole anti-parasitic drug being repurposed for cancer research
Why it matters: It targets tubulin, angiogenesis, ERK/MAPK-related signalling, HIFs, Akt, NF-κB, and tumour metabolism
Best-supported use today: Investigational adjunctive or repurposed-drug use, not standard-of-care replacement
Strongest evidence: Broad preclinical evidence with early human safety and small clinical signals
Main limitation: Human efficacy data remains early and not yet definitive
Why mebendazole is studied in oncology
Mebendazole has moved beyond its original anti-parasitic role because it appears to affect multiple cancer hallmarks at once.
Research suggests it may:
inhibit tubulin polymerisation and disrupt mitosis
suppress angiogenesis through VEGFR2-related effects
interfere with Akt, NF-κB, β-catenin, and HIF-related signalling
reduce metastatic behaviour in selected models
support anti-tumour immunity through context-dependent ERK effects
work as a useful partner in drug-repurposing strategies
Clinical Positioning
Current evidence best supports mebendazole as an investigational repurposed adjunct rather than a proven cancer therapy.
Its strongest current relevance is in the overlap between:
low-cost repurposed-drug interest
anti-angiogenic and anti-mitotic strategies
selected CNS and gastrointestinal cancer settings
combination protocols under clinician supervision
Evidence Quality Rating
3.5/5 — Moderate-to-strong preclinical evidence with emerging clinical data
This rating reflects broad mechanistic and preclinical evidence, plus early human safety and biomarker data, but limited large interventional cancer trials.
Where to Go Next
See also: Mebendazole and TP53
Key References
Mebendazole as a Candidate for Drug Repurposing in Oncology https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/
Emerging Perspectives on the Antiparasitic Mebendazole as a Cancer Therapy https://pmc.ncbi.nlm.nih.gov/articles/PMC9862092/
Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent https://ecancer.org/en/journal/article/443-repurposing-drugs-in-oncology-redo-mebendazole-as-an-anti-cancer-agent
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
Last updated
Was this helpful?